Per Med. 2018 Sep 26. doi: 10.2217/pme-2018-0074. [Epub ahead of print]
Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders: financial impact on a health plan.
To evaluate payer costs associated with treating psychiatric disorders utilizing a combinatorial pharmacogenomics test versus treatment-as-usual (TAU).
PATIENTS & METHODS:
Administrative claims data were analyzed from health plan members whose treatment was guided by GeneSight®Psychotropic testing (CPGx® cohort) and those who received TAU (TAU cohort). Reimbursed costs were calculated over the 12-month pre-index and post-index event periods.
205 CPGx and 478 TAU members were included. Post-index cost savings (US$5505) drove a per-member-per-month savings of US$0.07. Disease-specific analyses resulted in similar savings.
Use of CPGx yielded reduced spending for a commercial health plan across the patient population with psychiatric disorders, as well as among high-cost subpopulations.
CPGx®; anxiety; bipolar disorder; combinatorial pharmacogenomics; depression; economic utility; managed care; pharmacogenomics; pharmacogenomics testing; psychiatry
Free full text